Gene Therapy in the Neuroendocrine System

• Autores: Hereñú, Claudia Beatriz; Morel, Gustavo Ramón; Bellini, María José; Reggiani, Paula Cecilia; Sosa, Yolanda Elena; Brown, Oscar Alfredo; Goya, Rodolfo Gustavo; Arzt, Eduardo; Bronstein, Marcello; Guitelman, Mirtha
• Año de publicación: 2006
• Idioma: inglés
• Tipo de recurso: parte de libro
• Materia: Biología
• Institución: Universidad Nacional de La Plata

The implementation of experimental gene therapy in animal models of neuroendocrine diseases is an area of growing interest. In the hypothalamus, restorative gene therapy has been successfully implemented in Brattleboro rats, an arginine vasopressin (AVP) mutant which suffers from diabetes insipidus, and in Koletsky (fak/fak) and in Zucker (fa/fa) rats which have leptin receptor mutations that render them obese, hyperphagic and hyperinsulinemic. In the above models, viral vectors expressing AVP, leptin receptor b and proopiomelanocortin, respectively, were stereotaxically injected in the relevant hypothalamic regions. In rats, aging brings about a progressive degeneration and loss of hypothalamic tuberoinfundibular dopaminergic (TIDA) neurons, which are involved in the tonic inhibitory control of prolactin secretion and lactotropic cell proliferation. Stereotaxic injection of an adenoviral vector expressing insulin-like growth factor I corrected their chronic hyperprolactinemia and restored TIDA neuron numbers. Spontaneous intermediate lobe pituitary tumors in a retinoblastoma (Rb) gene mutant mouse were corrected by injection of an adenoviral vector expressing the human Rb cDNA and experimental prolactinomas in rats were partially reduced by intrapituitary injection of an adenoviral vector expressing the HSV1-thymidine kinase suicide gene. These results suggest that further implementation of gene therapy strategies in neuroendocrine models may be highly rewarding.
Instituto de Investigaciones Bioquímicas de La Plata